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An innovative and efficient route to the synthesis
of metal-based glycoconjugates: proof-of-
concept and potential applications†
Andrea Pettenuzzo, a Diego Montagner, b Patrick McArdle a and
Luca Ronconi *a
With a view to developing more efficient strategies to the functionalization of metallodrugs with carbo-
hydrates, we here report on an innovative and efficient synthetic route to generate gold(III) glycoconju-
gates in high yields and purity. The method is based on the initial synthesis of the zinc(II)-dithiocarbamato
intermediate [ZnII(SSC-Inp-GlcN)2] (Inp = isonipecotic moiety; GlcN = amino-glucose) followed by the
transfer of the glucoseisonipecoticdithiocarbamato ligand to the gold(III) center via transmetallation reac-
tion between the zinc(II) intermediate and K[AuIIIBr4] in 1 : 2 stoichiometric ratio, yielding the corres-
ponding glucose-functionalized gold(III)-dithiocarbamato derivative [AuIIIBr2(SSC-Inp-GlcN)]. No protec-
tion/deprotection of the amino-glucose scaffold and no chromatographic purification were needed. The
synthetic protocol was optimized for glucose precursors bearing the amino function at either the C2 or
the C6 position, and works in the case of both α and β anomers. The application of the synthetic strategy
was also successfully extended to other metal ions of biomedical interest, such as gold(I) and platinum(II),
to obtain [AuI(SSC-Inp-GlcN)(PPh3)] and [Pt
II(SSC-Inp-GlcN)2], respectively. All compounds were fully
characterized by elemental analysis, mid- and far-IR, mono- and multidimensional NMR spectroscopy,
and, where possible, X-ray crystallography. Results and potential applications are here discussed.
Introduction
Research aimed at designing novel synthetic carbohydrate
derivatives has been steadily expanding over the last two
decades owing to their potential biomedical applications.1
Glycosylation (that is, the biochemical process by which a
carbohydrate is covalently bound to the target biomolecule
such as proteins and lipids) is involved in many metabolic
events and affects a number of cellular processes, including
cell proliferation and differentiation, intercellular communi-
cations, and carbohydrate-mediated recognition processes
such as the immune response.2 Therefore, given the crucial
biological role played by carbohydrates, it is not surprising
that research in glycoscience has strong implications for bio-
technology and medicine in order to develop new therapeutic
agents for the treatment of various diseases.
Glycoconjugation (that is, the functionalization of drugs
with glucose or other carbohydrates) is currently under intense
investigation, and applications include: carbohydrate-based
drugs and vaccines, adjuvants, metabolic labelling of glyco-
structures, and glycan arrays for diagnostic purposes.3 To date,
several carbohydrate-derived or -containing drugs are mar-
keted, e.g. zanamivir (antiviral), acarbose (antidiabetic),
heparin and fondaparinux (anticoagulant), doxorubicin (anti-
cancer), epoetin alfa and darbepoetin alfa (anemia treatment),
hiberix (haemophilus B conjugate vaccine), menjugate (menin-
gitis C vaccine),4 and many more are currently under pre-clini-
cal and clinical trials.5
Within the field of chemotherapy, conjugation of anti-
cancer drugs to biomolecules has been successfully achieved
in recent years by developing, for example, antibody-drug6 and
folate-drug7 conjugates which are currently in clinical use.
Intriguingly, compared with peptides, synthetic carbohydrates
proved challenging to be obtained, mainly due to the complex-
ity of the traditional synthesis in solution. In particular,
difficulties associated with stereoselective glycosidic bond for-
mation and the extensive use of protecting groups (and sub-
sequent selective deprotection),8 resulted in lengthy multi-step
syntheses requiring several purifications of the various inter-
mediate products by column chromatography and, ultimately,
affording poor overall yields.9 The exploitation and optimiz-
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ation of alternative synthetic approaches, such as chemoenzy-
matic,10 automated solid-phase,11 and microwave-assisted12
synthesis, have substantially boosted the field in terms of
shorter reaction times and higher yields. On the other hand,
such techniques are not always exploitable for all glycoconju-
gates, especially when the carbohydrate functionalization is
applied to metal-containing substrates.
Owing to the potentiality of metallodrugs, the latest
approaches focus on the functionalization of metal-based
scaffolds with biologically-active ligands having tumor target-
ing properties (i.e. carriers), thereby maximizing the thera-
peutic outcomes on cancer cells and minimizing the occur-
rence of side-effects.13 A number of metal glycoconjugates
have been reported to date,14a,b especially glucose derivatives
in which conjugation occurs mainly at the anomeric C1 posi-
tion.14c–f Nevertheless, in most cases coordination of glucose-
like substrates to metal centers proved somewhat demanding
and involved several steps. For example, Lippard and co-
workers have recently reported on the synthesis of all possible
positional isomers (C1α, C1β, C2, C3, C4 and C6) of a glucose-
oxaliplatin conjugate.15 Remarkably, each isomer required
4–12 steps with yields of 15–30% (considering only the final
step leading to the corresponding platinum(II) glycoconjugate).
On the basis of the aforementioned considerations, given
our well-established expertise in the development of gold(III)-
dithiocarbamato complexes,16 we here report on an innovative,
facile and efficient synthetic route to the generation of gold(III)-
dithiocarbamato glycoconjugates. Our strategy relies on the
one-pot synthesis of a bis-dithiocarbamato-zinc(II) intermedi-
ate which can be subsequently functionalized with an amino-
glucose moiety. The desired glucosedithiocarbamato ligand is
then transferred to the gold(III) metal center via a zinc(II)–gold(III)
transmetallation reaction yielding the corresponding high
purity gold(III)-dithiocarbamato glycoconjugate in excellent
yields (70–90%) (Scheme 1). Remarkably, neither protection/
deprotection of the amino-glucose scaffold nor chromato-
graphic purification were required, and the transmetallation
reactions reached completion within a few hours.
In order to assess the potential of this synthetic protocol to
other metal ions, we applied the same procedure also to gold(I)
and platinum(II), and succeeded in generating the corres-
ponding glycoconjugates.
Experimental details and results are here discussed and
compared with the synthetic strategies currently available in
the literature.
Results and discussion
Rationale
In terms of medicinal applications, glycoconjugation can be
exploited to achieve the specific targeting and treatment of
cancer.17 This strategy relies on the evidence that rapidly divid-
ing tumor cells require higher amounts of nutrients and
energy to sustain their fast proliferation, including especially
glucose. In fact, glucose uptake proved to be 10 to 12-fold
higher in tumors compared with healthy tissues, and glucose
transporters (GLUTs), devoted to the recognition and cellular
internalization of glucose, are largely overexpressed in tumor
cells, thus indicating their strong dependence on such trans-
porters for their survival and growth.18 The fact that anaerobic
glycolysis is the major glucose metabolism in tumors is a
phenomenon called “the Warburg effect” (named after the
German biochemist Otto Warburg who first observed it),19 and
it is acknowledged nowadays as one of the hallmarks of
cancer.20 Consequently, such increased demand of glucose by
cancer cells makes it very attractive to selectively target tumor
sites. In particular, tailored glucose-like substrates can be con-
jugated to chemotherapeutics to attain the site-specific deliv-
ery of drugs into the affected tissues (i.e. targeted anticancer
chemotherapy and tumor imaging).21 This approach was
especially inspired by the evidence that the clinically-estab-
lished positron emission tomography (PET) tracer [18F]-fluoro-
deoxyglucose is preferentially taken up by cancer cells com-
pared with normal tissues,22 and has been recently extended
to the design of carbohydrate-based nanocarriers.23
As previously pointed out, the complexity of carbohydrate
chemistry may severely hamper glycoconjugation of drugs, in
particular when metal-based scaffolds are involved. Therefore
more efficient synthetic approaches to glyco-functionalization
are required. As shown in Scheme 1, our suggested strategy
relies on the pre-generation of a zinc(II)-dithiocarbamato glyco-
conjugate precursor followed by the transfer of the whole
dithiocarbamato ligand to the desired metal center through a
Scheme 1 General synthetic route to gold(III)-dithiocarbamato glycoconjugates.
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transmetallation reaction. Specifically, we developed a facile
and reproducible protocol in which an amino acidic linker is
functionalized with the dithiocarbamato moiety (–NCSS) at the
amino terminus, whereas the carboxylate tail is first activated
and then conjugated to an amino-sugar. The rationale of this
strategy is based on the following considerations.
• Dithiocarbamates are versatile monoanionic ligands
capable of stabilizing a wide range of metal ions by coordinat-
ing the metal center in either monodentate or chelating biden-
tate modes.24 Although referred to as “soft” Lewis bases (and,
thus, expected to coordinate mainly “soft” Lewis acids such as
low-valent metal ions), they may be also regarded as “hard”
ligands in the thioureide resonance form (Scheme 2), which
favors the binding of metals in higher oxidation states (i.e.
“hard” Lewis acids).25
Accordingly, dithiocarbamates can be used to coordinate a
number of metal ions in different oxidation states affording
stable complexes.26
• An added value of using dithiocarbamato ligands is that,
once coordinated to a bioactive metal center, they may act as
intrinsic chemoprotectants against the toxicity of metal-based
drugs, thus reducing their side-effects.27 Consequently, not
only metal-dithiocarbamato derivatives have been largely
explored in recent years as potential anticancer agents,25 but
the chemoprotective activity of the dithiocarbamato moiety
has been confirmed in vivo, in particular for gold(III)
derivatives.28
• Dithiocarbamates of primary and secondary amines are
generally synthesized by reaction with carbon disulfide (CS2)
under basic conditions (e.g. NaOH, KOH, Et3N) at low tempera-
ture, yielding the corresponding dithiocarbamato salts.29
Dithiocarbamates generated from primary amines are often
unstable and tend to decompose to give the corresponding iso-
thiocyanates.30 The secondary amine counterparts are gener-
ally more stable and a number of simple dithiocarbamates
have been prepared and isolated as sodium or ammonium
salts.31 Nevertheless, isolation and storage of free dithiocarba-
mates is often challenging since, at room temperature, they
may decompose back to the starting amine and CS2, especially
under acidic conditions.32 For this reason, dithiocarbamates
are best prepared in situ: once generated in solution they are
reacted with the metal precursor in the appropriate stoichio-
metric ratio to obtain the corresponding metal-dithiocarba-
mato derivative.25
In principle, direct functionalization of an amino-sugar
could be achieved. To the best of our knowledge, only one of
such example is reported in the literature. Zhang and co-
workers synthesized and isolated 2-deoxy-2-dithiocarbamato-D-
glucose as sodium salt by reacting D-glucosamine hydro-
chloride with CS2 and NaOH, and used it to obtain the corres-
ponding 99mTc-nitrido bis-dithiocarbamato complex.33
Unfortunately, when following the same experimental pro-
cedure, we could not obtain the analogous gold(III) complex.
Notwithstanding various attempts, the experimental con-
ditions employed always led to the reduction of gold(III) to gold(I)
and the simultaneous degradation of the carbohydrate scaffold
resulting from the intramolecular attack of the –NCSS group
located in the C2 position of the glucose to the anomeric site
(data not shown).34
• The use of an amino acidic linker between the dithiocar-
bamato function and the conjugated sugar has a two-fold
purpose. From a practical synthetic point of view it allows the
straightforward conversion of the amino terminus into an
–NCSS group35 without worrying about the possible side-reac-
tions involving the carbohydrate scaffold, should the latter be
present. On the other hand, the carboxylic function can be
easily activated with N,N,N′,N′-tetramethyl-O-(N-succinimidyl)
uronium (TSTU) and subsequently coupled to an amino-sugar
to attain glycoconjugation through the formation of an amide
bond.36
Moreover, from a biological perspective, if the final goal is
to target the GLUTs overexpressed in tumors to achieve selecti-
vity, the anomeric position of the glucose-like unit should be
sufficiently accessible to be recognized (and, thus, internalized
inside the tumor cell) by such transporters.21a Therefore, the
inclusion of a rigid linker (like the isonipecotic moiety used in
this work) would reduce the steric hindrance around the
anomeric site of the sugar, thus allowing, at least in principle,
its recognition by GLUTs.
Model non-glycosylated gold(III)-dithiocarbamato complexes
Taking into account the aforementioned issues, we first evalu-
ated the feasibility of our synthetic approach by generating
non-glycosylated gold(III)-dithiocarbamato complexes via trans-
metallation from the corresponding zinc(II) intermediates
(Scheme 3). Specifically, we focused on ethyl isonipecotate
(Inp-OEt) and isonipecotamide (Inp-NH2) dithiocarbamates as
model ligands since their amino group is a symmetric second-
ary amine and, as such, can lead to very stable, symmetric
compounds.26
Amongst our numerous initial attempts to isolate free
dithiocarbamates, we succeeded in obtaining only one, that is,
isonipecotamidedithiocarbamate as sodium salt (Na(SSC-Inp-
NH2), Fig. 1; see the ESI† for details).
Both [ZnII(SSC-Inp-OEt)2] (Zn1) and [Zn
II(SSC-Inp-NH2)2]
(Zn2) were obtained in a one-pot reaction. Zn2 was obtained
also by reacting the free ligand Na(SSC-Inp-NH2) with
[ZnII(OAc)2] in 2 : 1 ratio.
Zinc(II) is a “borderline” Lewis acid37 and, although it
forms stable covalent adducts with the “soft” dithiocarbamato
ligands,26 it is well-known to serve as a source of such ligands
for a softer metal (possibly much more reliable and controlla-
ble than the commonly employed ionic sodium, potassium or
ammonium dithiocarbamato salts).38 Therefore, zinc(II) dithio-Scheme 2 Resonance forms of the dithiocarbamato ligands.
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carbamates may undergo transmetallation reactions with
many “soft” transition metals, including gold(III).39 In this
regard, the zinc(II)–gold(III) transmetallation reaction was opti-
mized in DMF, yielding the gold(III) counterparts
[AuIIIBr2(SSC-Inp-OEt)] (Au1) and [Au
IIIBr2(SSC-Inp-NH2)] (Au2)
in high yields (>70%) and no need of further purification.
IR spectroscopy proved useful to identify the synthesized
compounds. By comparison with the spectra recorded for the
starting ethyl isonipecotate and isonipecotamide reagents (see
the ESI† for details), the appearance of a strong band at 1494
(Zn1)/1492 (Zn2) cm−1 in the zinc(II) derivatives (the so-called
“thioureide” band, ν(N–CSS)) is consistent with a chelating
dithiocarbamato ligand coordinated to a zinc(II) center.40
When taking into account the gold(III) counterparts, the ν(N–
CSS) is recorded at higher frequencies (1571 (Au1)/1565 (Au2)
cm−1) due to the increased electron-withdrawing effect upon
moving from zinc(II) to the more positively charged gold(III)
center, suggesting a greater contribution of the “thioureide”
resonance form (Scheme 2).41 Additionally, the detection of a
single band at ca. 1000 cm−1 in all complexes (attributed to
the νa(SCS)) clearly supports a symmetrical bidentate coordi-
nation of the –NCSS moiety to the metal centers, in agreement
with the Bonati–Ugo criterion.42
In the far-IR spectra of a number of metal-dithiocarbamato
complexes, bands recorded in the range 420–320 cm−1 are
regarded as highly diagnostic since they are assigned to the
metal–sulfur stretching vibrations. Zn1 and Zn2 show an
intense absorption at ca. 395 cm−1 originating from the
νa(ZnS4),
43 whereas the corresponding symmetric stretching is
absent as it is not IR-active in the tetrahedral bis-dithiocarba-
mato zinc derivatives.44 On the contrary, both νa,s(SAuS) are
recorded for the square-planar Au1 and Au2 complexes (at 413/
Scheme 3 Synthesis of the model (i.e. non-glycosylated) gold(III)-dithiocarbamato derivatives via transmetallation.
Fig. 1 X-ray crystal structure with atom numbering scheme for Na
(SSC-Inp-NH2) (CCDC 1835869†) (50% displacement ellipsoids).
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398 and 411/397 cm−1, respectively), in agreement with those
reported in the literature for similar gold(III)-dithiocarba-
mates.45 Finally, other informative bands are observed at lower
frequencies for the latter complexes at 249/228 (Au1) and 232/
227 (Au2) cm−1, attributed to the νa,s(BrAuBr) for terminal cis-
bromides.46
Mono- and multinuclear NMR spectroscopy provided
further insights into the identification of the dithiocarbamato
complexes. For example, compared with the starting ethyl iso-
nipecotate reagent, a general downfield shift of the proton
signals is observed for the zinc(II) intermediate Zn1 and the
corresponding transmetallation product Au1 (Fig. 2). This is
consistent with the decreased electron density experienced by
the hydrogen atoms of the isonipecotate scaffold upon intro-
ducing the dithiocarbamato moiety and the subsequent
coordination to the metal centers, the gold(III) ion exerting
greater deshielding than zinc(II) due to the higher oxidation
state.47 As expected, the larger shift involves the piperidine
hydrogens, the only partial exception to this trend being the
C2′,6′H equatorial protons which undergo a 0.7 ppm upfield
shift in Au1 with respect to Zn1. On moving away from the
dithiocarbamato moiety, the magnitude of the chemical shift
change decreases until being negligible for the farther ester
group.
The most diagnostic peak recorded in the 13C{1H} NMR
spectra is attributed to the dithiocarbamic carbon atom and is
generally found in the range 180–220 ppm.48 It is generally
assumed that the 13C chemical shifts of the –NCSS moiety are
strongly dependent on both the type of metal-dithiocarbamate
bonding and the oxidation state of the metal center. As to the
dithiocarbamato complexes of transition metals owning a d10
electron configuration (such as zinc(II)), the δ(N13CSS) peaks
are recorded in the range 202–206 ppm,49 whereas for deriva-
tives of high oxidation state transition metals (such as
gold(III)), the dithiocarbamic carbon signals appear upfield.50
There is a strong empirical correlation between δ(N13CSS)
values and the N–CSS stretching vibrations in the infrared
spectra: higher ν(N–CSS) values indicate an increased carbon–
nitrogen double bond character, which well correlates with
lower δ(N13CSS) values because of a greater electron density on
the –NCSS moiety, and the other way round.48 All these con-
siderations are fully consistent with the experimental ν(N–CSS)
frequencies and the N13CSS carbon signals recorded for the
object dithiocarbamato complexes (202.6 (Zn1), 202.3 (Zn2),
187.9 (Au1) and 186.9 (Au2) ppm).
Crystals suitable for X-ray diffraction crystallography were
obtained for Zn1 and Au1 (Fig. 3). Although crystal structures
of monomeric bis-dithiocarbamato-zinc(II) complexes are
known, which have highly strained structures with two four-
membered rings,51 a common arrangement for this class of
compounds is dinuclear centrosymmetric,52 and this was
observed also for Zn1. Dimeric structures, in which one four-
membered zinc(II)-dithiocarbamato ring is retained whereas
the other has opened to form an eight-membered ring, were
first reported for the bis-diethyldithiocarbamato-zinc(II)
complex,53 and have since been reported for several other ana-
logous derivatives.54 Relief of distortion is the most likely
reason for the adoption of the dimeric structure, and the angle
at the zinc(II) center in the four-membered ring is 75.79(4)°.
As to the crystal structure of Au1, there is distortion from
square-planar geometry due to the small bite angle of the
dithiocarbamato ligand. However, there the maximum devi-
ation from the least-squares plane defined by the gold(III)
center and the ligating atoms of 0.008 Å is shown by S1 and
S2. The bond distances are in the range previously reported
and are close to those found in other dibromo-dithiocarba-
mato-gold(III) complexes.55,56a Interestingly, the zinc(II)-dithio-
carbamato complex Zn1 has Zn–S distances within the four-
membered rings which differ by a near constant 0.1 Å, whereas
in the gold(III) counterpart Au1 the Au–S distances have differ-
ences which are ten times smaller. Further details of the struc-
tures are provided in the ESI.†
Analogous gold(III)-dithiocarbamato complexes have been
previously obtained through one-pot template reactions,41,56
Fig. 2 Comparison of the 1H NMR spectra in DMSO-D6 of ethyl isoni-
pecotate, [ZnII(SSC-Inp-OEt)2] (Zn1) and [Au
IIIBr2(SSC-Inp-OEt)] (Au1).
Fig. 3 X-ray crystal structure with atom numbering scheme for Zn1
(CCDC 1835870†) and Au1 (CCDC 1835871†) (50% displacement
ellipsoids).
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invariably resulting in a mixture of two forms (whose relative
abundance varies depending on the synthetic conditions), that
is, the expected gold(III) derivative and a dimeric form in
which two bridging dithiocarbamato ligands are bound to
both gold(III) centers whose coordination sphere is completed
by two trans-bromide moieties.57 Remarkably, our zinc(II)–
gold(III) transmetallation strategy led to the generation of the
expected monomeric form only.
Gold(III)-dithiocarbamato glycoconjugates
Following the successful generation of the model non-glycosy-
lated gold(III)-dithiocarbamato complexes, we applied the same
synthetic strategy to obtain the corresponding glycoconjugate
counterparts. With reference to Scheme 4, we first prepared
the zinc(II)-dithiocarbamato derivative of isonipecotic acid,
Na2[Zn
II(SSC-Inp-O)2]·2H2O (Zn0a), by optimizing a literature
procedure.58 In order to conjugate the amino-sugars to the
isonipecotic linker, the carboxylic functions of Zn0a were sub-
sequently activated by converting them into the corresponding
succinimidyl ester, [ZnII(SSC-Inp-OSu)2] (Zn0b). Although this
is a well-known process, common synthetic routes involve the
use of acidic media in which dithiocarbamates tend to decom-
pose.32 Therefore, we exploited the method reported by Suades
and co-workers which makes use of the peptide coupling
reagent N,N,N′,N′-tetramethyl-O-(N-succinimidyl)uronium
tetrafluoroborate (TSTU) in presence of N,N-diisopropyl-
ethylamine (DIPEA).52 This procedure proved very efficient and
straightforward also because Zn0b could be easily isolated
from the DMF reaction medium by simple precipitation after
addition of a 1 : 1 water/ethanol mixture. Both Zn0a and Zn0b
were obtained in high yield (68% and 93%, respectively) and
purity, and their spectroscopic characterization was fully con-
sistent with literature data.52
As far as the amino-sugar substrates are concerned, we
chose three different glucose-like scaffolds (see the ESI† for
details on syntheses and characterizations).
• 2-Amino-2-deoxy-(α,β)-D-glucose (aka (α,β)-D-glucosamine,
GlcN1) hydrochloride, bearing the amino function in the C2
position of the glucose, is commercially available and is sold
as a mixture of α and β anomers (the former largely predomi-
Scheme 4 Synthesis of the zinc(II)-dithiocarbamato glycoconjugate precursors. (a) CS2 (1 eq.), NaOH (2 eq.), MeOH, 0 °C, 6 h; (b) [Zn(OAC)2]·2H2O
(0.5 eq.), MeOH, r.t.; (c) TSTU (2.2. eq.), DIPEA (0.2 eq.), anhyd. DMF, r.t., N2, 16 h; (d) (GlcN2)·(HCl) (2.5 eq.), DIPEA (7.5 eq.), anhyd. DMF, r.t., N2, 16 h;
(e) (GlcN2)(CH3COOH) (2.4 eq.), DIPEA (1 eq.), anhyd. DMF, r.t., N2, 16 h; (f ) (GlcN3) (2.5 eq.), DIPEA (5.5 eq.), anhyd. DMF, r.t., N2, 16 h.
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nating). Glucosamine-appended ligands have been already
used in some cases to obtain metal-glycoconjugates.21b,c
• 1-O-Methyl-2-amino-2-deoxy-(α,β)-D-glucopyranoside (GlcN2)
was prepared as ammonium acetate according to a literature
procedure.59 An α : β anomers ratio of approximately 5 : 1 was
obtained. Methylation of the anomeric hydroxyl group (C1 posi-
tion) aimed at avoiding side-reactions involving the anomeric
carbon in the subsequent steps, as well as at simplifying the
NMR characterization of the final products.
• 1-O-Methyl-6-amino-6-deoxy-α-D-glucopyranoside (GlcN3)
was prepared according to a literature procedure60 with the
aim of investigating the feasibility of our synthetic method for
amino-sugars bearing the amino function in positions other
than the C2 site of the glucose (i.e. C6 position).
An excess of each amino-sugar (2.4–2.5 eq.) was reacted
with the activated zinc(II) precursor Zn0b in anhydrous DMF
under basic conditions (DIPEA), leading to the coupling of the
amino function of the glucose-like unit to the carboxylic group
of the isonipecotic moiety, thus resulting in the formation an
amide bond and the generation of the corresponding com-
plexes [ZnII(SSC-Inp-GlcN1)2] (Zn3), [Zn
II(SSC-Inp-GlcN2)2]
(Zn4) and [ZnII(SSC-Inp-GlcN3)2] (Zn5) (Scheme 4).
By comparing the spectroscopic features of the starting
reagents with those of the zinc(II)-dithiocarbamato glycoconju-
gates, the most affected signals were those related to the
atoms in close proximity to the newly formed amide bond. In
the IR spectra of Zn3–Zn5 the absorption bands originating
from both the succinimidyl fragment of Zn0b (νip(CvO succi-
nimidyl), νoop(CvO succinimidyl) and ν(CvO ester) at 1817,
1780 and 1737 cm−1)52 and from the amino/ammonium group
of the sugar substrates GlcN1–GlcN3 (νa(NH3
+), νs(NH3
+),
δa(NH3
+), δs(NH3
+), ν(NH2) and δ(NH2) at ∼3090, 2840, 1620,
1580, 3260 and 1600 cm−1, respectively)61 disappeared.
Instead, new intense bands at ∼1640 (ν(CvO, amide I)) and
∼1550 (δip(CNH, amide II)) cm−1 were detected,62 consistent
with the replacement of the succinimidyl ester located in the
same position by an amide group. On the contrary, ν(N–CSS),
νa(SCS), νs(SCS) and νa(ZnS4) remained substantially
unchanged (at ∼1490, 1000, 570 and 370 cm−1, respectively)
compared with Zn0b. Analogously, the 1H and 13C{1H} NMR
signals corresponding to the zinc(II)-dithiocarbamato isonipe-
cotic fragment and the glucose moiety recorded for Zn3–Zn5
were observed at chemical shifts similar to those found for the
starting reagents, except the peaks associated with the C4′H
group of the piperidine ring, and the C2H group (for Zn3 and
Zn4) or the C6H2 group (for Zn5) of the glucose unit.
Eventually, zinc(II)–gold(III) transmetallation was achieved
by reacting the zinc(II) precursors Zn3–Zn5 with K[AuIIIBr4] in
DMF, affording the final corresponding gold(III)-dithiocarba-
mato glycoconjugates [AuIIIBr2(SSC-Inp-GlcN1)] (Au3),
[AuIIIBr2(SSC-Inp-GlcN2)] (Au4) and [Au
IIIBr2(SSC-Inp-GlcN3)]
(Au5) (Scheme 5) in high yields (>75%) and no need of further
purification. The synthesized gold(III) complexes were charac-
terized by the usual analytical and spectroscopic techniques.
In the mid-IR spectra the ν(N–CSS) band shifted from ∼1490 to
∼1560 cm−1, as a result of the increased electron-withdrawing
effect in the gold(III) derivatives compared with the zinc(II)
counterparts, whereas in the far-IR spectra the absorptions at
∼370 cm−1 (νa(ZnS4)) disappeared and new bands at ∼410/390
(νa,s(SAuS)) and ∼245/225 (νa,s(BrAuBr)) cm−1 were recorded
instead, consistent with the expected dibromide-gold(III)-
dithiocarbamato scaffold.
In line with what is observed for the model non-glycosylated
complexes (see above), when moving from the zinc(II) to the
gold(III) glycoconjugates, major changes in the NMR spectra
were detected for the signals associated with the isonipecotic-
dithiocarbamato fragments. A comparative example is given in
Fig. 4 for Au5. Remarkably, as a general trend, the 1H signals
recorded for the glucose hydroxyl groups are properly resolved
only for the zinc(II) intermediates, whereas for both the start-
ing amino-sugars and the corresponding gold(III) derivatives
peaks tend to collapse into a single very broad band (Fig. 5A).
Scheme 5 Synthesis of the gold(III)-dithiocarbamato glycoconjugates via transmetallation.
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In terms of the reactivity of the different anomers, the α to
β ratio was substantially retained when using (α,β)-D-glucos-
amine (GlcN1). On the contrary, the percent of the α anomer
dramatically increased by moving from O-methyl-2-amino-2-
deoxy-D-glucopyranoside (GlcN2, α : β ≈ 5 : 1) to the corres-
ponding zinc(II)-dithiocarbamato glycoconjugate (Zn4, α : β ≈
25 : 1), the β anomer being completely absent in the gold(III)
analogue (Au4). This was assessed by measuring the 3J (C1H,
C2H) coupling constants in the 1H NMR spectra which were in
the 1–4 Hz and 6–8 Hz for the α and β anomers, respectively.63
Finally, 1-O-methyl-6-amino-6-deoxy-D-glucopyranoside (GlcN3)
was obtained in its α anomeric form only and, as expected, no
α to β anomerization processes occurred.
Gold(I)- and platinum(II)-dithiocarbamato glycoconjugates
The feasibility of the glycoconjugation strategy here proposed
was assessed also towards metal centers other than gold(III). By
reacting the zinc(II) precursors Zn4 and Zn5 with 2 eq. of
[AuICl(PPh3)] in DMF, the corresponding gold(I)-dithiocarba-
mato derivatives [AuI(SSC-Inp-GlcN2)(PPh3)] (Au6) and
[AuI(SSC-Inp-GlcN3)(PPh3)] (Au7) were obtained (Scheme 6)
and characterized by elemental analysis, IR and NMR spec-
troscopy. Consistently with other triphenylphosphino-gold(I)-
dithiocarbamato complexes reported in the literature,64 those
gold(I) compounds were expected to exhibit a near-linear geo-
metry around the metal center with the dithiocarbamato
scaffold acting as a monodentate ligand. Although attempts to
grow crystals of Au6 and Au7 proved unsuccessful, the pro-
posed molecular structure was confirmed by the presence in
the mid-IR spectra of two bands at ca. 1000 and 914 cm−1
assignable to the stretching vibration of the SvC–S moiety.
This is in agreement with the Bonati–Ugo criterion, according
to which a split band in the 1050–900 cm−1 spectral region
with a splitting larger than 20 cm−1 indicates monodentate
bonding of the dithiocarbamato ligand.65
Compared with the gold(III) counterparts Au4 and Au5, the
1H and 13C peaks of the glucosedithiocarbamato scaffold are
recorded at similar chemical shifts with the exception of the
atoms closer to the gold(I) core, which are more sensitive to
the different metal center and coordination mode of the
–NCSS group. In particular, a significant downfield shift is
observed for the C2′,6′Heq (
1H: ∼4.9 ppm (+0.7 ppm); 13C:
∼51 ppm (+2 ppm)) and the NCSS (13C: ∼203 ppm (+16 ppm))
Fig. 4 Comparison of the 1H (A) and 13C{1H} (B) NMR spectra in
DMSO-D6 of 1-O-methyl-6-amino-6-deoxy-α-D-glucopyranoside
(GlcN3), [ZnII(SSC-Inp-GlcN3)2] (Zn5) and [Au
IIIBr2(SSC-Inp-GlcN3)]
(Au5).
Fig. 5 Comparison of the 1H (A) and 13C{1H} (B) NMR spectra in
DMSO-D6 of [Zn
II(SSC-Inp-GlcN3)2] (Zn5) and [Pt
II(SSC-Inp-GlcN3)2]
(Pt2).
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moieties which, together with the detection of the ν(N–CSS)
vibration at lower energy (∼1485 cm−1 (−70 cm−1)), are consist-
ent with a smaller electron-withdrawing effect upon moving
from the gold(III) to the less positively charged gold(I) center.41
Glycoconjugation via transmetallation was achieved also in
presence of platinum(II). Reaction of the zinc(II) precursors Zn4
and Zn5 with (PPh4)[Pt
IICl3(NH3)] led to the formation of the
complexes [PtII(SSC-Inp-GlcN2)2] (Pt1) and [Pt
II(SSC-Inp-
GlcN3)2] (Pt2) (Scheme 6), although the original plan was to
synthesize the corresponding mono-dithiocarbamato deriva-
tives [PtIICl(SSC-Inp-GlcN)(NH3)]. In fact, notwithstanding
various attempts and the exploitation of different experimental
conditions, the replacement of all the chlorido and amino
ligands with two dithiocarbamato ligands occurred, even when
a large excess (5 eq.) of the starting platinum(II) reagent was
used.
Although no crystals of the platinum(II) glycoconjugates
were obtained, elemental analysis and spectroscopic results
support the formation of the bis-dithiocarbamato adducts. In
this regard, the N–CSS stretching vibrations observed at 1523
and 1554 cm−1 (compared with the same absorption recorded
at ∼1494 cm−1 for the zinc(II) precursors) are in agreement
with data reported in the literature for analogous bis-dithiocar-
bamato-platinum(II) derivatives.66 Moreover, the absence in the
IR spectra of the bands associated with both the NH3 ligand
(at ∼3200 (νa,s), ∼1640 (δa), ∼1290 (δs), ∼780 (ρ) cm−1) and the
chloride ligand (ν(Pt–Cl) at ∼330 cm−1)67 supports the hypoth-
esis of a complete exchange of ligands in favor of the dithiocar-
bamato ligands.
As far as the NMR characterization is concerned, an illustra-
tive example is given in Fig. 5. The 1H and 13C{1H} spectra of
Pt2 are very clean and clearly indicate the presence of only one
species in solution. Although the majority of the signals res-
onate at chemical shifts almost identical to those of their
counterparts in the zinc(II) precursor Zn5, Pt2 is undoubtedly a
different compound, as evidenced by the major upfield shift of
the 1H and 13C peaks associated with the C2′,6′Heq group.
Moreover, the 13C peak at 207 ppm assigned to the dithiocar-
bamato carbon atom is fully consistent with those reported in
the literature for other bis-dithiocarbamato-platinum(II)
derivatives.66a
Remarkably, no signals attributable to the NH3 ligand were
observed in the 1H NMR spectra. In this regard, we synthesized
the 15N-labeled analogues of Pt1 and Pt2 by reacting Zn4 and
Zn5 with the platinum(II) precursor (PPh4)[Pt
IICl3(
15NH3)], and
both the IR and NMR spectra turned out to be identical to
those of the unlabeled counterparts (data not shown). In par-
ticular, no 15N peaks were recorded in the corresponding
[1H,15N] HSQC spectra, thus confirming that the NH3 ligand
was replaced.
Notwithstanding the desired mono-dithiocarbamato-plati-
num(II) glycoconjugates were not obtained, the transmetalla-
tion reaction proved successful anyway. In perspective, this
issue might be overcome by using organophosphino (instead
of amino) platinum(II) precursors as recently reported.68
Conclusions
We have developed a relatively facile and efficient synthetic
strategy to the functionalization of metal complexes with
carbohydrates based on the initial synthesis of the zinc(II)-
dithiocarbamato glycoconjugate intermediates followed by the
transfer of the glucosedithiocarbamato ligand to other metal
centers via transmetallation. Although transmetallation of
dithiocarbamates has been known for decades, to the best of
our knowledge, its systematic application to glycoconjugation
has not been reported to date.
The main features of the proposed synthetic route are the
following.
Scheme 6 Synthesis of the gold(I)- and platinum(II)-dithiocarbamato glycoconjugates via transmetallation.
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• It proved successful with different amino-glucose sub-
strates, and no protection/deprotection of the glucose units
nor chromatographic purification were required. We are now
planning to extend this procedure to more complex amino-
sugars, including oligosaccharides.
• Compared with the common dithiocarbamato sodium,
potassium and ammonium salts, zinc(II)-dithiocarbamato
glycoconjugate precursors are reasonably stable over time, can
be synthesized in bulk in high yields and purity, and stored
safely for subsequent transmetallation reactions.
• Transmetallation was achieved in high yields and purity
for different metal ions, such as gold(III), gold(I) and platinum
(II). We are now in the process of exploiting the same approach
with organometallic-gold(III), carbene-gold(I) and carbonyl-
manganese(I) precursors.
Given the potential biological applications of metal glyco-
conjugates, in particular for the targeted metal-based chemo-
therapy and diagnosis, the synthetic protocol here optimized
and proposed may be applied to a number of different metal
scaffolds, thus being of interest for scientists working in the
field of medicinal inorganic and bioinorganic chemistry.
Experimental section
Materials and general methods (including instrumentation
used) are available in the ESI.†
Amino-sugar precursors
2-Amino-2-deoxy-(α,β)-D-glucose (aka (α,β)-D-glucosamine,
GlcN1) hydrochloride was commercially available, whereas 1-
O-methyl-2-amino-2-deoxy-(α,β)-D-glucopyranoside (GlcN2)59
and 1-O-methyl-6-amino-6-deoxy-α-D-glucopyranoside
(GlcN3),60 were synthesized according to literature procedures.
Detailed syntheses and characterizations are reported in the
ESI.†
Zinc(II)-dithiocarbamato intermediates
Na2[Zn
II(SSC-Inp-O)2]·2H2O (Zn0a). This zinc(II) intermedi-
ate was synthesized according to a modified literature pro-
cedure.58 NaOH (620.0 mg, 15.50 mmol) was dissolved in
methanol (7 mL) and added under stirring to a methanol solu-
tion (10 mL) of isonipecotic acid (1.00 g, 7.74 mmol). The
mixture was cooled down to 0 °C, treated dropwise with CS2
(480 μL, 7.94 mmol), and stirred for 6 h. The resulting solution
was then added dropwise under stirring to a methanol solu-
tion (7 mL) of [Zn(OAc)2]·2H2O (850.0 mg, 3.87 mmol), leading
to the sudden precipitation of a white solid. The precipitate
was centrifuged and the bulk of supernatant discarded. The
residue was subsequently washed with methanol (3 × 20 mL)
and then dried under vacuum over P2O5, yielding the title com-
pound as a white solid (1.47 g, 68%). M.p. 295–297 °C (dec.).
Anal. (%) calcd for C14H22N2Na2O6S4Zn (MM = 553.94
g mol−1): C, 30.36; H, 4.00; N, 5.06; found: C, 30.48; H, 4.08; N,
5.04. FT-IR (CsI disk; 298 K): v˜max 1555 (νa, COO
−), 1487
(ν, N–CSS), 1409 (νs, COO
−), 1002 (νa, SCS), 566 (νs, SCS), 397
(νa, ZnS4) cm
−1. 1H NMR (400 MHz; D2O; 298 K): δ 4.93 (4 H,
br dt, C2′,6′Heq), 3.31 (4 H, br td, C
2′,6′Hax), 2.46 (2 H, tt, C
4′H),
1.95 (4 H, dd, C3′,5′Heq), 1.66 (4 H, qd, C
3′,5′Hax) ppm.
13C{1H}
NMR (100 MHz; D2O; 298 K): δ 201.6 (NCSS), 183.1 (COO
−),
51.8 (C2′,6′H2), 42.8 (C
4′H), 28.8 (C3′,5′H2) ppm.
[ZnII(SSC-Inp-OSu)2] (Zn0b). This zinc(II) intermediate was
synthesized according to a literature procedure.52 N,N,N′,N′-
Tetramethyl-O-(N-succinimidyl)uronium tetrafluoroborate
(TSTU, 3.07 g, 10.2 mmol) was added under stirring to an
anhydrous DMF suspension (12 mL) of Zn0a (2.51 g,
4.53 mmol) and N,N-diisopropylethylamine (DIPEA, 160 μL,
0.92 mmol). The mixture was stirred at room temperature
under inert atmosphere (N2) for 16 h and then treated with a
1 : 1 water/ethanol solution (1.2 L), affording a white solid. The
precipitate was filtered off, washed with ethanol (3 × 20 mL)
and diethyl ether (3 × 20 mL), and then dried under vacuum
over P2O5, yielding the title compound as a white solid (2.81 g,
93%). M.p. 220–222 °C (dec.). Anal. (%) calcd for
C22H26N4O8S4Zn (MM = 668.09 g mol
−1): C, 39.55; H, 3.92; N,
8.39; found: C, 39.31; H, 3.98; N, 8.28. FT-IR (CsI disk; 298 K):
v˜max 1817 (νip, CvO succinimidyl), 1784 (νoop, CvO succinimi-
dyl), 1737 (ν, CvO ester), 1496 (ν, N–CSS), 1206 (ν, C–OSu),
1001 (νa, SCS), 562 (νs, SCS), 397 (νa, ZnS4) cm
−1. 1H NMR
(400 MHz; DMSO-D6; 298 K): δ 4.72 (4 H, br d, C
2′,6′Heq), 3.52
(4 H, br t, C2′,6′Hax), 3.26–3.19 (2 H, m, C
4′H), 2.82 (8 H, s, CH2
succinimidyl), 2.10 (4 H, dd, C3′,5′Heq), 1.70 (4 H, qd, C
3′,5′Hax)
ppm. 13C{1H} NMR (100 MHz; DMSO-D6; 298 K): δ 203.3
(NCSS), 170.2 (CvO succinimidyl), 169.9 (CvO ester), 49.9
(C2′,6′H2), 36.3 (C
4′H), 27.6 (C3′,5′H2), 25.5 (CH2 succinimidyl)
ppm.
[ZnII(SSC-Inp-OEt)2] (Zn1). CS2 (400 μL, 6.63 mmol) was
added dropwise under stirring to a water/ethanol (7 : 3, 10 mL)
solution of ethyl isonipecotate (1.03 g, 6.53 mmol) at 0 °C. The
mixture was stirred at 0 °C for 3 h (pH turned from 12 to 6),
and then added to an aqueous solution (3 mL) of ZnCl2
(220.0 mg, 1.63 mmol), leading to the sudden precipitation of
a white solid. The precipitate was centrifuged and the bulk of
supernatant discarded. The residue was subsequently washed
with water (2 × 10 mL), acetone (2 × 10 mL) and diethyl ether
(2 × 10 mL), and then dried under vacuum over P2O5, yielding
the title compound as a white solid (620.1 mg, 72%). Small
colorless plate-shaped crystals suitable for X-ray crystallogra-
phy were obtained upon slow evaporation of an acetonitrile/
ethanol solution of the compound. M.p. 200–202 °C. Anal. (%)
calcd for C18H28N2O4S4Zn (MM = 530.05 g mol
−1): C, 40.79; H,
5.32; N, 5.29; found: C, 40.57; H, 5.39; N, 5.10. FT-IR (CsI disk;
298 K): v˜max 1733 (ν, CvO), 1494 (ν, N–CSS), 1176 (ν, C–OEt),
1042 (ν, O–Et), 1007 (νa, SCS), 568 (νs, SCS), 398 (νa, ZnS4)
cm−1. 1H NMR (400 MHz; DMSO-D6; 298 K): δ 4.72 (4 H, dt,
C2′,6′Heq), 4.08 (4 H, q, OCH2), 3.39 (4 H, td, C
2′,6′Hax),
2.72–2.60 (2 H, m, C4′H), 1.95 (4 H, dd, C3′,5′Heq), 1.57 (4 H, qd,
C3′,5′Hax), 1.19 (6 H, t, CH3) ppm.
13C{1H} NMR (100 MHz;
DMSO-D6; 298 K): δ 202.6 (NCSS), 173.6 (CvO), 60.2 (OCH2),
50.4 (C2′,6′H2), 38.9 (C
4′H), 27.8 (C3′,5′H2), 14.1 (CH3) ppm.
[ZnII(SSC-Inp-NH2)2] (Zn2). Method A: NaOH (310.0 mg,
7.80 mmol) was dissolved in methanol (10 mL) and added
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under stirring to a methanol solution (10 mL) of isonipecota-
mide (1.00 g, 7.80 mmol). The mixture was cooled down to
0 °C, treated dropwise with CS2 (470 μL, 7.80 mmol), stirred
for 3 h (pH turned from 12 to 8), treated with further CS2
(470 μL, 7.80 mmol), and stored at 4 °C for 16 h. The mixture
was then added to an aqueous solution (2 mL) of
[Zn(OAc)2]·2H2O (860.0 mg, 3.90 mmol) at room temperature,
leading to the sudden precipitation of a white solid. The pre-
cipitate was centrifuged and the bulk of supernatant
discarded. The residue was subsequently washed with water
(2 × 15 mL) and then dried under vacuum over P2O5, yielding
the title compound as a white solid (1.77 g, 96%).
Method B: An aqueous solution (18 mL) of Na(SSC-Inp-
NH2)·CH3OH (900.0 mg, 3.48 mmol; see ESI† for details on
synthesis and characterization) was added under stirring to an
aqueous solution (2 mL) of [Zn(OAc)2]·2H2O (380.0 mg,
1.73 mmol) at room temperature, leading to the sudden pre-
cipitation of a white solid. The precipitate was centrifuged and
the bulk of supernatant discarded. The residue was sub-
sequently washed with water (2 × 15 mL) and then dried under
vacuum over P2O5, yielding the title compound as a white
solid (810.0 mg, 99%).
M.p. 293–294 °C (dec.). Anal. (%) calcd for C14H22N4O2S4Zn
(MM = 471.98 g mol−1): C, 35.63; H, 4.70; N, 11.87; found: C,
35.74; H, 4.89; N, 11.76. FT-IR (CsI disk; 298 K): v˜max 3439/
3208 (νa,s, NH2), 1667 (ν, CvO (amide I)), 1649 (δip, CNH2
(amide II)), 1492 (ν, N–CSS), 1007 (νa, SCS), 561 (νs, SCS), 392
(νa, ZnS4) cm
−1. 1H NMR (400 MHz; DMSO-D6; 298 K): δ 7.36
(2 H, s, NHcis), 6.87 (2 H, s, NHtrans), 4.82 (4 H, br d, C
2′,6′Heq),
3.26 (4 H, td, C2′,6′Hax), 2.40 (2 H, tt, C
4′H), 1.82 (4 H, dd,
C3′,5′Heq), 1.54 (4 H, qd, C
3′,5′Hax) ppm.
13C{1H} NMR
(100 MHz; DMSO-D6; 298 K): δ 202.3 (NCSS), 175.6 (CvO),
50.7 (C2′,6′H2), 40.1 (C
4′H), 28.4 (C3′,5′H2) ppm.
[ZnII(SSC-Inp-GlcN1)2] (Zn3). A mixture of (α,β)-D-glucos-
amine (GlcN1) hydrochloride (392.0 mg, 1.82 mmol) and N,N-
diisopropylethylamine (DIPEA, 925 μL, 5.31 mmol) in anhy-
drous DMF (3 mL) was added under stirring to a suspension of
Zn0b (473.3 mg, 0.71 mmol) in anhydrous DMF (2 mL). The
mixture was stirred at room temperature under inert atmo-
sphere (N2) for 16 h and then treated with methanol (60 mL),
leading to the sudden precipitation of a white solid. The pre-
cipitate was filtered off, washed with methanol (3 × 20 mL),
and then dried under vacuum over P2O5, yielding the title com-
pound as a white solid (341.6 mg, 61%). M.p. 200–203 °C
(dec.). Anal. (%) calcd for C26H42N4O12S4Zn (MM = 796.26 g
mol−1): C, 39.22; H, 5.32; N, 7.04; found: C, 39.18; H, 5.19; N,
6.91. FT-IR (CsI disk; 298 K): v˜max 3293br (ν, OH + NH over-
lapped), 1638 (ν, CvO (amide I)), 1547 (δip, CNH (amide II)),
1487 (ν, N–CSS), 1071br/1060br (ν, C–OH), 1005 (νa, SCS), 570
(νs, SCS), 373 (νa, ZnS4) cm
−1. 1H NMR (400 MHz; DMSO-D6;
298 K): δ 7.70 (0.5 H, d, NH β), 7.67 (2 H, d, NH α), 6.49 (0.5 H,
d, C1OH β), 6.41 (2 H, d, C1OH α), 4.94–4.90 (4 H, m, C3OH +
C1H α overlapped), 4.85–4.78 (5 H, br m, C2′,6′Heq α and β over-
lapped), 4.61 (2 H, d, C4OH α), 4.53 (0.5 H, dd, C6OH β),
4.45–4.42 (2.5 H, br m, C6OH α + C1H β overlapped), 3.69–3.39
(11.5 H, m, C2H α + C4H α and β + C5H α + C6H2 α and β over-
lapped), 3.31–3.22 (6 H, m, C2′,6′Hax α and β + C2H β + C3H β
overlapped), 3.18–3.02 (2.5 H, m, C3H α + C5H β overlapped),
2.57–2.52 (2.5 H, m, C4′H α and β overlapped), 1.81–1.75 (5 H,
m, C3′,5′Heq α and β overlapped), 1.62–1.56 (5 H, br qd, C3′,5′Hax
α and β overlapped) ppm. C3OH β and C4OH β could not be
undoubtedly assigned: those peaks are probably overlapped
with other peaks in the 4.92–4.42 ppm range. 13C{1H} NMR
(100 MHz; DMSO-D6; 298 K): δ 202.2 (NCSS), 173.8 (CvO),
95.4 (C1H β), 90.5 (C1H α), 76.9 (C5H β), 74.2 (C3H β), 72.1 (C5H
α), 71.1 (C3H α), 70.9 (C4H β), 70.4 (C4H α), 61.2 (C6H2 β), 61.1
(C6H2 α), 57.1 (C2H β), 54.3 (C2H α), 50.8 (C2′,6′H2), 40.1 (C4′H),
28.5 (C3′,5′H2) ppm. No differentiation of the
13C signals of the
isonipecotic moiety due to the presence of both α and β
anomers could be observed. Solution α : β anomers ratio ≈4 : 1
(based on the 1H NMR spectrum).
[ZnII(SSC-Inp-GlcN2)2] (Zn4). A mixture of 1-O-methyl-2-
amino-2-deoxy-(α,β)-D-glucopyranoside (GlcN2) (266.1 mg,
1.05 mmol) and N,N-diisopropylethylamine (DIPEA, 76 μL,
0.44 mmol) in anhydrous DMF (2 mL) was added under stir-
ring to a suspension of Zn0b (292.8 mg, 0.44 mmol) in anhy-
drous DMF (2 mL). The mixture was stirred at room tempera-
ture under inert atmosphere (N2) for 16 h and treated with
methanol (30 mL), leading to the formation of a white precipi-
tate that was filtered off and discarded. The resulting clear
pale yellow solution was allowed to slowly concentrate under
the fume hood at room temperature for two days. The resulting
white solid was resuspended in methanol (20 mL), filtered off,
washed with methanol (3 × 20 mL), and then dried under
vacuum over P2O5, yielding the title compound as a white
solid (464.6 mg, 35%). M.p. 268–272 °C (dec.). Anal. (%) calcd
for C28H46N4O12S4Zn (MM = 824.31 g mol
−1): C, 40.80; H, 5.63;
N, 6.80; found: C, 40.65; H, 5.74; N, 6.81. FT-IR (CsI disk;
298 K): v˜max 3319br (ν, OH + NH overlapped), 1645 (ν, CvO
(amide I)), 1557 (δip, CNH (amide II)), 1494 (ν, N–CSS), 1062br/
1040br (ν, C–OH + C
1–O–CH3 overlapped), 1007 (νa, SCS), 576
(νs, SCS), 366 (νa, ZnS4) cm
−1. 1H NMR (400 MHz; DMSO-D6;
298 K): δ 7.80 (2 H, d, NH), 5.00 (2 H, d, C4OH), 4.82 (4 H, br d,
C2′,6′Heq), 4.73 (2 H, d, C
3OH), 4.56–4.52 (4 H, m, C6OH + C1H
overlapped), 3.67–3.42 (8 H, m, C2H + C3H + C6H2 overlapped),
3.33–3.24 (6 H, m, C5H + C2′,6′Hax overlapped), 3.24 (6 H, s,
OCH3), 3.15–3.09 (2 H, m, C
4H), 2.59–2.52 (2 H, m, C4′H),
1.81–1.76 (4 H, br m, C3′,5′Heq), 1.57 (4 H, br qd, C
3′,5′Hax) ppm.
The 1H NMR signals refer to the α anomer. Signals related to
the β anomer were hardly detectable, and only a very few were
observed and could be undoubtedly assigned (such as δ(NH) =
7.68, δ(C3OH) = 4.91, δ(C1H) = 4.19 (3J1,2 = 8.4 Hz), δ(OCH3) =
3.58 (ppm). 13C{1H} NMR (100 MHz; DMSO-D6; 298 K): δ 202.2
(NCSS), 173.9 (CvO), 97.9 (C1H), 72.8 (C5H), 70.8 (C3H), 70.7
(C4H), 60.9 (C6H2), 54.5 (OCH3), 53.8 (C
2H), 50.8 (C2′,6′H2), 40.0
(C4′H), 28.5 (C3′,5′H2) ppm. No
13C signals assignable to the
β anomer were detected. Solution α : β anomers ratio ≈25 : 1
(based on the 1H NMR spectrum).
[ZnII(SSC-Inp-GlcN3)2] (Zn5). A mixture of 1-O-methyl-6-
amino-6-deoxy-α-D-glucopyranoside (GlcN3, 760.0 mg,
3.93 mmol) and N,N-diisopropylethylamine (DIPEA, 1.50 mL,
8.64 mmol) in anhydrous DMF (4 mL) was added under stir-
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ring to a suspension of Zn0b (1.05 g, 1.57 mmol) in anhydrous
DMF (4 mL). The mixture was stirred at room temperature
under inert atmosphere (N2) for 16 h and then treated with
ethanol (80 mL), leading to the sudden precipitation of a white
solid. The precipitate was filtered off, washed with methanol
(3 × 15 mL), and then dried under vacuum over P2O5, yielding
the title compound as a white solid (980.0 mg, 76%).
M.p. 245–248 °C (dec.). Anal. (%) calcd for C28H46N4O12S4Zn
(MM = 824.31 g mol−1): C, 40.80; H, 5.63; N, 6.80; found:
C, 40.91; H, 5.83; N, 6.76. FT-IR (CsI disk; 298 K): v˜max 3392br
(ν, OH + NH overlapped), 1637 (ν, CvO (amide I)), 1543 (δip,
CNH (amide II)), 1494 (ν, N–CSS), 1050br (ν, C–OH + C
1–O–CH3
overlapped), 1010 (νa, SCS), 564 (νs, SCS), 366 (νa, ZnS4) cm
−1.
1H NMR (400 MHz; DMSO-D6; 298 K): δ 7.97 (2 H, dd, NH),
4.97 (2 H, d, C4OH), 4.83 (4 H, br m, C2′,6′Heq), 4.82 (2 H, d,
C3OH), 4.75 (2 H, d, C2OH), 4.51 (2 H, d, C1H, 3J1,2 = 3.6 Hz),
3.58–3.52 (2 H, m, C6H′), 3.40–3.35 (4 H, m, C3H + C5H over-
lapped), 3.24 (6 H, s, OCH3), 3.28–3.19 (6 H, m, C
2H + C2′,6′Hax
overlapped), 3.08–2.98 (2 H, m, C6H″), 2.92–2.88 (2 H, m, C4H),
2.57–2.53 (2 H, m, C4′H), 1.78–1.75 (4 H, m, C3′,5′Heq), 1.57
(4 H, br qd, C3′,5′Hax) ppm.
13C{1H} NMR (100 MHz; DMSO-D6;
298 K): δ 202.2 (NCSS), 173.8 (CvO), 99.6 (C1H), 73.0 (C3H),
72.1 (C4H), 72.0 (C2H), 70.3 (C5H), 54.3 (OCH3), 50.7 (C
2′,6′H2),
39.9 (C4′H), 39.8 (C6H2), 28.4 (C
3′,5′H2) ppm.
Gold(III)-dithiocarbamato complexes
[AuIIIBr2(SSC-Inp-OEt)] (Au1). A DMF solution (2 mL) of Zn1
(76.5 mg, 0.15 mmol) was added dropwise under stirring to a
DMF solution (2 mL) of K[AuBr4]·2H2O (170.5 mg, 0.30 mmol)
at room temperature. The mixture was stirred for 3 h, after
which the color of the solution turned from dark red to
orange. Addition of a diethyl ether/n-hexane 2 : 1 solution
(60 mL) resulted in the formation of a light orange precipitate.
The precipitate was centrifuged and the bulk of supernatant
discarded. The residue was subsequently washed with ethanol
(15 mL) and a water/ethanol 1 : 1 solution (2 × 15 mL), and
then dried under vacuum over P2O5, yielding the title com-
pound as an orange solid (132.2 mg, 78%). Orange shiny plate-
shaped crystals suitable for X-ray crystallography were obtained
upon slow evaporation of an acetone solution of the com-
pound. M.p. 243–246 °C (dec.). Anal. (%) calcd for
C9H14AuBr2NO2S2 (MM = 589.11 g mol
−1): C, 18.35; H, 2.40; N,
2.38; found: C, 18.27; H, 2.39; N, 2.25. FT-IR (CsI disk; 298 K):
v˜max 1729 (ν, CvO), 1571 (ν, N–CSS), 1183 (ν, C–OEt), 1040
(ν, O–Et), 1002 (νa, SCS), 536 (νs, SCS), 413 (νa, SAuS), 398 (νs,
SAuS), 249 (νa, BrAuBr), 228 (νs, BrAuBr) cm
−1. 1H NMR
(400 MHz; DMSO-D6; 298 K): δ 4.09 (2 H, q, OCH2), 4.07–4.05
(2 H, m, C2′,6′Heq), 3.61 (2 H, td, C
2′,6′Hax), 2.90 (1 H, tt, C
4′H),
2.08 (2 H, dd, C3′,5′Heq), 1.75 (2 H, qd, C
3′,5′Hax), 1.19 (3 H, t,
CH3) ppm.
13C{1H} NMR (100 MHz; DMSO-D6; 298 K): δ 187.9
(NCSS), 173.2 (CvO), 60.9 (OCH2), 48.6 (C
2′,6′H2), 39.0 (C
4′H),
27.3 (C3′,5′H2), 14.6 (CH3) ppm.
[AuIIIBr2(SSC-Inp-NH2)] (Au2). A suspension of Zn2 (42.0 mg,
0.09 mmol) in DMF (8 mL) was added dropwise under stirring
to a DMF solution (2 mL) of K[AuBr4]·2H2O (105.4 mg,
0.18 mmol) at room temperature. The mixture was stirred for
1.5 h, after which the suspension dissolved completely and the
color of the solution turned from dark red to orange. Addition of
diethyl ether (100 mL) led to the precipitation of an orange
residue. The precipitate was centrifuged and the bulk of super-
natant discarded. The residue was subsequently washed with
methanol (3 × 15 mL) and then dried under vacuum over P2O5,
yielding the title compound as an orange solid (69.3 mg, 70%).
M.p. 268–272 °C (dec.). Anal. (%) calcd for C7H11AuBr2N2OS2
(MM = 560.07 g mol−1): C, 15.01; H, 1.98; N, 5.00; found: C,
15.06; H, 2.09; N, 4.96. FT-IR (CsI disk; 298 K): v˜max 3408/3176
(νa,s, NH2), 1660 (ν, CvO (amide I)), 1620 (δip, CNH2 (amide II)),
1565 (ν, N–CSS), 1007 (νa, SCS), 534 (νs, SCS), 411 (νa, SAuS), 397
(νs, SAuS), 232 (νa, BrAuBr), 227 (νs, BrAuBr) cm
−1. 1H NMR
(400 MHz; DMSO-D6; 298 K): δ 7.40 (2 H, s, NHcis), 6.97 (2 H, s,
NHtrans), 4.11 (2 H, dt, C
2′,6′Heq), 3.57 (2 H, td, C
2′,6′Hax), 2.62
(1 H, tt, C4′H), 1.97 (2 H, dd, C3′,5′Heq), 1.62 (2 H, qd, C
3′,5′Hax)
ppm. 13C{1H} NMR (100 MHz; DMSO-D6; 298 K): δ 186.9 (NCSS),
174.5 (CvO), 48.4 (C2′,6′H2), 40.3 (C
4′H), 27.5 (C3′,5′H2) ppm.
[AuIIIBr2(SSC-Inp-GlcN1)] (Au3). A DMF solution (2 mL) of
Zn3 (74.3 mg, 0.09 mmol) was added dropwise under stirring
to a DMF solution (2 mL) of K[AuBr4]·2H2O (110.5 mg,
0.19 mmol) at room temperature. The mixture was stirred for
3 h, after which the color of the solution turned from dark red
to orange. Addition of diethyl ether (40 mL) resulted in the for-
mation of an orange precipitate. The precipitate was centri-
fuged and the bulk of supernatant discarded. The residue was
subsequently washed with methanol (3 × 10 mL) and then
dried under vacuum over P2O5, yielding the title compound as
an orange solid (100.9 mg, 75%). M.p. 210–211 °C (dec.). Anal.
(%) calcd for C13H21AuBr2N2O6S2 (MM = 722.21 g mol
−1): C,
21.62; H, 2.93; N, 3.88; found: C, 21.78; H, 3.03; N, 3.78. FT-IR
(CsI disk; 298 K): v˜max 3306br (ν, OH + NH overlapped), 1636 (ν,
CvO (amide I)), 1561 (ν, N–CSS + δip, CNH (amide II) over-
lapped), 1060br (ν, C–OH), 1008 (νa, SCS), 575 (νs, SCS), 412 (νa,
SAuS), 392 (νs, SAuS), 244 (νa, BrAuBr), 227 (νs, BrAuBr) cm
−1.
1H NMR (400 MHz; DMSO-D6; 298 K): δ 7.75 (0.4 H, d, NH β),
7.73 (1 H, d, NH α), 6.45 (1.4 H, br s, C1OH α and β over-
lapped), 4.91 (1 H, d, C1H α, 3J1,2 = 3.1 Hz), 4.45 (0.4 H, d, C1H
β, 3J1,2 = 7.8 Hz), 4.12 (2.8 H, br dt, C2′,6′Heq α and β over-
lapped), ∼4.0 (4.2 H, br s, C3OH + C4OH + C6OH α and β over-
lapped), 3.69–3.39 (9 H, m, C2H α + C4H α and β + C5H α +
C6H2 α and β, C2′,6′Hax α and β overlapped), 3.37–3.23 (0.8 H,
m, C2H β + C3H β overlapped), 3.11–3.04 (1.4 H, m, C3H α +
C5H β overlapped), 2.75 (1 H, tt, C4′H α), 2.63 (0.4 H, tt, C4′H β),
1.98–1.91 (2.8 H, br m, C3′,5′Heq α and β overlapped), 1.75–1.67
(2.8 H, br m, C3′,5′Hax α and β overlapped) ppm. 13C{1H} NMR
(100 MHz; DMSO-D6; 298 K): δ 186.9 (NCSS α; β not detected),
172.8 (CvO α), 172.7 (CvO β), 95.3 (C1H β), 90.5 (C1H α), 76.9
(C5H β), 74.2 (C3H β), 72.1 (C5H α), 71.1 (C3H α), 70.8 (C4H β),
70.4 (C4H α), 61.2 (C6H2 β), 61.1 (C6H2 α), 57.2 (C2H β), 54.3
(C2H α), 48.4 (C2′,6′H2 α), 48.3 (C2′,6′H2 β), 40.5 (C4′H β), 40.1
(C4′H α), 27.8 (C3′,5′H2 α), 27.3 (C3′,5′H2 β) ppm. Solution α : β
anomers ratio ≈2.5 : 1 (based on the 1H NMR spectrum).
[AuIIIBr2(SSC-Inp-GlcN2)] (Au4). A DMF solution (2 mL) of
Zn4 (88.6 mg, 0.11 mmol) was added dropwise under stirring
to a DMF solution (3 mL) of K[AuBr4]·2H2O (128.6 mg,
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0.22 mmol) at room temperature. The mixture was stirred for
3 h, after which the color of the solution turned from dark red
to orange. Addition of diethyl ether (50 mL) resulted in the for-
mation of an orange precipitate. The precipitate was centri-
fuged and the bulk of supernatant discarded. The residue was
subsequently washed with methanol (3 × 10 mL) and then
dried under vacuum over P2O5, yielding the title compound as
an orange solid (129.1 mg, 81%). M.p. 198–202 °C (dec.). Anal.
(%) calcd for C14H23AuBr2N2O6S2 (MM = 736.24 g mol
−1): C,
22.84; H, 3.15; N, 3.81; found: C, 22.85; H, 2.98; N, 3.75. FT-IR
(CsI disk; 298 K): v˜max 3400br/3296br (ν, OH + NH overlapped),
1649 (ν, CvO (amide I)), 1561 (ν, N–CSS + δip, CNH (amide II)
overlapped), 1059br/1040br (ν, C–OH + C
1–O–CH3 overlapped),
1007 (νa, SCS), 577 (νs, SCS), 410 (νa, SAuS), 393 (νs, SAuS), 246
(νa, BrAuBr), 220 (νs, BrAuBr) cm
−1. 1H NMR (400 MHz;
DMSO-D6; 298 K): δ 7.86 (1 H, d, NH), 4.97 (3 H, br s, C
3OH +
C4OH + C6OH overlapped), 4.52 (1 H, d, C1H, 3J1,2 = 3.5 Hz),
4.12 (2 H, br dt, C2′,6′Heq), 3.68–3.27 (7 H, m, C
2′,6′Hax + C
2H +
C3H + C5H + C6H2 overlapped), 3.24 (3 H, s, OCH3), 3.12 (1 H,
dd, C4H), 2.75 (1 H, tt, C4′H), 1.98–1.91 (2 H, m, C3′,5′Heq),
1.76–1.66 (2 H, m, C3′,5′Hax) ppm.
13C{1H} NMR (100 MHz;
DMSO-D6; 298 K): δ 186.9 (NCSS), 172.9 (CvO), 97.8 (C
1H),
72.8 (C5H), 70.8 (C3H), 70.7 (C4H), 60.8 (C6H2), 54.4 (OCH3),
53.7 (C2H), 48.4 (C2′,6′H2), 40.3 (C
4′H), 27.7 (C3′,5′H2) ppm. No
NMR signals assignable to the β anomer were detected.
[AuIIIBr2(SSC-Inp-GlcN3)] (Au5). A DMF solution (3 mL) of
Zn5 (101.7 mg, 0.12 mmol) was added dropwise under stirring
to a DMF solution (3 mL) of K[AuBr4]·2H2O (148.8 mg,
0.25 mmol) at room temperature. The mixture was stirred for
2 h, after which the color of the solution turned from dark red to
orange. Addition of diethyl ether (60 mL) resulted in the for-
mation of an orange precipitate. The precipitate was centrifuged
and the bulk of supernatant discarded. The residue was sub-
sequently washed with methanol (3 × 10 mL) and then dried
under vacuum over P2O5, yielding the title compound as an
orange solid (161.2 mg, 87%). M.p. 217–220 °C (dec.). Anal. (%)
calcd for C14H23AuBr2N2O6S2 (MM = 736.24 g mol
−1): C, 22.84;
H, 3.15; N, 3.81; found: C, 22.95; H, 3.07; N, 3.78. FT-IR (CsI
disk; 298 K): v˜max 3400br (ν, OH + NH overlapped), 1650 (ν, CvO
(amide I)), 1555 (ν, N–CSS + δip, CNH (amide II) overlapped),
1050br (ν, C–OH + C
1–O–CH3 overlapped), 1011 (νa, SCS), 570 (νs,
SCS), 398br (νa,s, SAuS), 254 (νa, BrAuBr), 227 (νs, BrAuBr) cm
−1.
1H NMR (400 MHz; DMSO-D6; 298 K): δ 7.99 (1 H, dd, NH), 4.51
(1 H, d, C1H, 3J1,2 = 3.6 Hz), 4.13 (2 H, br d, C
2′,6′Heq), 3.60 (3 H,
br s, C2OH + C3OH + C4OH overlapped), 3.59–3.53 (3 H, m, C6H′
+ C2′,6′Hax overlapped), 3.37–3.30 (2 H, m, C
3H + C5H overlapped),
3.24 (3 H, s, OCH3), 3.21–3.17 (1 H, m, C
2H), 3.05–2.94 (1 H, m,
C6H″), 2.90 (1 H, dd, C4H), 2.71 (1 H, br tt, C4′H), 1.93 (2 H, td,
C3′,5′Heq), 1.71 (2 H, qd, C
3′,5′Hax) ppm.
13C{1H} NMR (100 MHz;
DMSO-D6; 298 K): δ 187.0 (NCSS), 172.7 (CvO), 99.6 (C
1H), 73.0
(C3H), 72.1 (C4H), 71.9 (C2H), 70.3 (C5H), 54.4 (OCH3), 48.4
(C2′,6′H2), 40.5 (C
4′H), 40.1 (C6H2), 27.7 (C
3′,5′H2) ppm.
Gold(I)-dithiocarbamato complexes
[AuI(SSC-Inp-GlcN2)(PPh3)] (Au6). A DMF solution (2 mL) of
Zn4 (65.0 mg, 0.08 mmol) was added dropwise under stirring
to a DMF solution (2 mL) of [AuCl(PPh3)] (78.0 mg,
0.16 mmol) at room temperature, and the mixture was stirred
for 1 h. Upon addition of diethyl ether (40 mL), the solution
turned cloudy and a white solid residue formed. The precipi-
tate was centrifuged and the bulk of supernatant discarded.
The sticky residue was subsequently triturated with a 1 : 1
diethyl ether/dichloromethane mixture (3 × 10 mL), and then
dried under vacuum over P2O5, yielding the title compound as
a light yellow solid (80.2 mg, 60%). M.p. 188–190 °C (dec.).
Anal. (%) calcd for C32H38AuN2O6PS2 (MM = 838.72 g mol
−1):
C, 45.83; H, 4.57; N, 3.34; found: C, 45.92; H, 4.63; N, 3.29.
FT-IR (CsI disk; 298 K): v˜max 3424br (ν, OH + NH overlapped),
1651 (ν, CvO (amide I)), 1545 (δip, CNH (amide II)), 1490
(ν, N–CSS), 1100 (νq vib, P–Ph3), 1056br (ν, C–OH + C
1–O–CH3
overlapped), 1001/914 (ν, SvC–S), 710/694 (νr vib, P–Ph3), 578
(ν, C–S), 539/509/500 (δy vib, P–Ph3), 427 (νt vib, P–Ph3), 380
(ν, Au–S), 273/240 (δx vib, P–Ph3 + ν, Au–P) cm
−1. 1H NMR
(400 MHz; DMSO-D6; 298 K): δ 7.80 (1 H, d, NH), 7.59–7.50 (15
H, m, CH Ph), 5.01 (1 H, d, C4OH), 4.90 (2 H, br dt, C2′,6′Heq),
4.71 (1 H, d, C3OH), 4.55 (1 H, d, C6OH), 4.53 (1 H, d, C1H,
3J1,2 = 3.1 Hz), 3.68–3.61 (2 H, m, C
2H + C6H′ overlapped),
3.49–3.42 (2 H, m, C3H + C6H″ overlapped), 3.33–3.26 (3 H, m,
C2′,6′Hax + C
5H overlapped), 3.24 (3 H, s, OCH3), 3.15–3.09 (1 H,
m, C4H), 2.59–2.53 (1 H, br tt, C4′H), 1.83–1.75 (2 H, m,
C3′,5′Heq), 1.65–1.55 (2 H, m, C
3′,5′Hax) ppm.
13C{1H} NMR
(100 MHz; DMSO-D6; 298 K): δ 202.2 (NCSS), 173.9 (CvO),
133.5 (d, o-CH, 2JC,P = 14.3 Hz), 131.9 (d, p-CH,
4JC,P = 2.0 Hz),
130.1 (d, CP, 1JC,P = not detectable due to overlapping), 129.5
(d, m-CH, 3JC,P = 11.3 Hz), 97.9 (C
1H), 72.8 (C5H), 70.8 (C3H),
70.7 (C4H), 60.8 (C6H2), 54.5 (OCH3), 53.8 (C
2H), 50.8 (C2′,6′H2),
40.3 (C4′H), 28.4 (C3′,5′H2) ppm.
31P{1H} NMR (162 MHz;
DMSO-D6; 298 K): δ 36.5 (AuPPh3) ppm.
[AuI(SSC-Inp-GlcN3)(PPh3)] (Au7). A DMF solution (2 mL) of
Zn5 (67.0 mg, 0.08 mmol) was added dropwise under stirring
to a DMF solution (2 mL) of [AuCl(PPh3)] (80.4 mg,
0.16 mmol) at room temperature, and the mixture was stirred
for 1 h. Upon addition of diethyl ether (40 mL), the solution
turned cloudy and a white solid residue formed. The precipi-
tate was centrifuged and the bulk of supernatant discarded.
The sticky residue was subsequently triturated with a 1 : 1
diethyl ether/dichloromethane mixture (3 × 10 mL), and then
dried under vacuum over P2O5, yielding the title compound as
a light yellow solid (95.2 mg, 70%). M.p. 162–166 °C (dec.).
Anal. (%) calcd for C32H38AuN2O6PS2 (MM = 838.72 g mol
−1):
C, 45.83; H, 4.57; N, 3.34; found: C, 45.96; H, 4.56; N, 3.39.
FT-IR (CsI disk; 298 K): v˜max 3429br (ν, OH + NH overlapped),
1654 (ν, CvO (amide I)), 1544 (δip, CNH (amide II)), 1483 (ν,
N–CSS), 1101 (νq vib, P–Ph3), 1051br (ν, C–OH + C
1–O–CH3 over-
lapped), 1000/914 (ν, SvC–S), 711/694 (νr vib, P–Ph3), 577 (ν,
C–S), 539/510/500 (δy vib, P–Ph3), 437 (νt vib, P–Ph3), 397 (ν, Au–
S), 262/241 (δx vib, P–Ph3 + ν, Au–P) cm
−1. 1H NMR (400 MHz;
DMSO-D6; 298 K): δ 7.98 (1 H, dd, NH), 7.60–7.52 (15 H, m, CH
Ph), 4.98 (1 H, d, C4OH), 4.89 (2 H, br d, C2′,6′Heq), 4.82 (1 H, d,
C3OH), 4.76 (1 H, d, C2OH), 4.51 (1 H, d, C1H, 3J1,2 = 3.7 Hz),
3.55 (1 H, ddd, C6H′), 3.38–3.33 (2 H, m, C3H + C5H over-
lapped), 3.24 (3 H, s, OCH3), 3.24–3.17 (3 H, m, C
2H + C2′,6′Hax
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overlapped), 3.01 (1 H, td, C6H″), 2.93–2.87 (1 H, m, C4H), 2.55
(1 H, br tt, C4′H), 1.79–1.75 (2 H, m, C3′,5′Heq), 1.65–1.56 (2 H,
m, C3′,5′Hax) ppm.
13C{1H} NMR (100 MHz; DMSO-D6; 298 K):
δ 203.6 (NCSS), 173.9 (CvO), 133.7 (d, o-CH, 2JC,P = 15.7 Hz),
131.9 (d, p-CH, 4JC,P = 2.8 Hz), 129.8 (d, CP,
1JC,P = not detect-
able due to overlapping), 129.5 (d, m-CH, 3JC,P = 11.9 Hz), 99.6
(C1H), 73.0 (C3H), 72.1 (C4H), 72.0 (C2H), 70.3 (C5H), 54.3
(OCH3), 51.2 (C
2′,6′H2), 40.5 (C
4′H), 40.1 (C6H2), 28.5 (C
3′,5′H2)
ppm. 31P{1H} NMR (162 MHz; DMSO-D6; 298 K): δ 36.5
(AuPPh3) ppm.
Platinum(II)-dithiocarbamato complexes
[PtII(SSC-Inp-GlcN2)2] (Pt1). A DMF solution (2 mL) of Zn4
(15.2 mg, 0.02 mmol) was added dropwise under stirring to a
DMF solution (2 mL) of (PPh4)[PtCl3(NH3)] (24.4 mg,
0.04 mmol) at room temperature. The mixture was stirred for
16 h and then treated with diethyl ether (40 mL). The resulting
cloudy solution was stored at 4 °C for 1 h, leading to the for-
mation of a yellow precipitate. The precipitate was centrifuged
and the bulk of supernatant discarded. The residue was sub-
sequently washed with a 1 : 1 methanol/dichloromethane solu-
tion (3 × 10 mL) and then dried under vacuum over P2O5, yield-
ing the title compound as a yellow solid (12.2 mg, 35%). M.
p. 195–198 °C (dec.). Anal. (%) calcd for C28H46N4O12PtS4 (MM
= 954.02 g mol−1): C, 35.25; H, 4.86; N, 5.87; found: C, 35.14;
H, 4.95; N, 5.81. FT-IR (CsI disk; 298 K): v˜max 3401br (ν, OH +
NH overlapped), 1650 (ν, CvO (amide I)), 1523 (ν, N–CSS + δip,
CNH (amide II) overlapped), 1055br (ν, C–OH + C
1–O–CH3 over-
lapped), 1005 (νa, SCS), 577 (νs, SCS), 365 (νa, PtS4) cm
−1. 1H
NMR (400 MHz; DMSO-D6; 298 K): δ 7.84 (2 H, d, NH), 5.01
(2 H, d, C4OH), 4.73 (2 H, d, C3OH), 4.56–4.52 (4 H, m, C6OH +
C1H overlapped), 4.20–4.16 (4 H, br d, C2′,6′Heq), 3.67–3.62
(4 H, m, C2H + C6H′ overlapped), 3.49–3.40 (4 H, m, C3H +
C6H″ overlapped), 3.33–3.24 (6 H, m, C5H + C2′,6′Hax over-
lapped), 3.24 (6 H, s, OCH3), 3.15–3.09 (2 H, m, C
4H), 2.64
(2 H, tt, C4′H), 1.90–1.83 (4 H, br m, C3′,5′Heq), 1.60–1.51 (4 H,
br m, C3′,5′Hax) ppm.
13C{1H} NMR (100 MHz; DMSO-D6;
298 K): δ 207.2 (NCSS), 173.4 (CvO), 97.8 (C1H), 72.8 (C5H),
70.8 (C3H), 70.7 (C4H), 60.8 (C6H2), 54.4 (OCH3), 53.8 (C
2H),
46.1 (C2′,6′H2), 40.4 (C
4′H), 27.9 (C3′,5′H2) ppm. No NMR signals
assignable to the β anomer were detected.
[PtII(SSC-Inp-GlcN3)2] (Pt2). A DMF solution (2 mL) of Zn5
(34.8 mg, 0.04 mmol) was added dropwise under stirring to a
DMF solution (2 mL) of (PPh4)[PtCl3(NH3)] (55.6 mg,
0.08 mmol) at room temperature. The mixture was stirred for
16 h and then treated with diethyl ether (40 mL). The resulting
cloudy solution was stored at 4 °C for 1 h, leading to the for-
mation of an oily yellow residue. The residue was centrifuged
and the bulk of supernatant discarded. The oily residue was
subsequently triturated with dichloromethane (10 mL) to
obtain a yellow solid which was filtered off, washed with di-
chloromethane (3 × 10 mL), and then dried under vacuum
over P2O5, yielding the title compound as a yellow solid
(40.0 mg, 49%). M.p. 217–220 °C (dec.). Anal. (%) calcd for
C28H46N4O12PtS4 (MM = 954.02 g mol
−1): C, 35.25; H, 4.86; N,
5.87; found: C, 35.34; H, 5.06; N, 5.84. FT-IR (CsI disk; 298 K):
v˜max 3393br/3324br (ν, OH + NH overlapped), 1647 (ν, CvO
(amide I)), 1554 (ν, N–CSS + δip, CNH (amide II) overlapped),
1048br (ν, C–OH + C
1–O–CH3 overlapped), 1007 (νa, SCS), 566
(νs, SCS), 350 (νa, PtS4) cm
−1. 1H NMR (400 MHz; DMSO-D6;
298 K): δ 7.99 (2 H, dd, NH), 4.98 (2 H, d, C4OH), 4.83 (2 H, d,
C3OH), 4.76 (2 H, d, C2OH), 4.51 (2 H, d, C1H, 3J1,2 = 3.3 Hz),
4.18 (4 H, br d, C2′,6′Heq), 3.55 (2 H, br dd, C
6H′), 3.37–3.34
(4 H, m, C3H + C5H overlapped), 3.24 (6 H, s, OCH3), 3.24–3.19
(6 H, m, C2H + C2′,6′Hax overlapped), 3.05–2.95 (2 H, m, C
6H″),
2.90 (2 H, br td, C4H), 2.60 (2 H, br tt, C4′H), 1.86–1.83 (4 H, m,
C3′,5′Heq), 1.57–1.52 (4 H, m, C
3′,5′Hax) ppm.
13C{1H} NMR
(100 MHz; DMSO-D6; 298 K): δ 207.2 (NCSS), 173.3 (CvO),
99.7 (C1H), 73.0 (C3H), 72.1 (C4H), 72.0 (C2H), 70.3 (C5H), 54.3
(OCH3), 46.1 (C
2′,6′H2), 40.7 (C
4′H), 40.1 (C6H2), 28.0 (C
3′,5′H2)
ppm.
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